Lesson plan
FLUORETH-LAD
FLUORETH-LAD (TRALA-15), or FE-LAD, also known as 6-(2-fluoroethyl)-LAD or 6-(2-fluoroethyl)-6-nor-LSD, is a lysergamide derivative. It was first proposed by Alexander and Ann Shulgin in their book TiHKAL, but was never synthesised by Shulgin. Synthesis and activity data for the compound were first reported in a 2022 patent by Matthias Grill, in which pharmacological testing showed it to have similar affinity to LSD at some targets such as the 5-HT 1A and 5-HT 2A serotonin receptors, but much lower affinity at other targets such as 5-HT 2C and at dopamine receptors, giving it comparatively greater selectivity compared to LSD. Currently new lysergamide derivates are in the development phase at MiHKAL GmbH in Switzerland.
Article summary
FLUORETH-LAD (TRALA-15), or FE-LAD, also known as 6-(2-fluoroethyl)-LAD or 6-(2-fluoroethyl)-6-nor-LSD, is a lysergamide derivative. It was first proposed by Alexander and Ann Shulgin in their book TiHKAL, but was never synthesised by Shulgin. Synthesis and activity data for the compound were first reported in a 2022 patent by Matthias Grill, in which pharmacological testing showed it to have similar affinity to LSD at some targets such as the 5-HT 1A and 5-HT 2A serotonin receptors, but much lower affinity at other targets such as 5-HT 2C and at dopamine receptors, giving it comparatively greater selectivity compared to LSD. Currently new lysergamide derivates are in the development phase at MiHKAL GmbH in Switzerland.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.